Neoadjuvant ‘Full Dose’ oxaliplatin/capecitabine/radiotherapy for MRI selected ‘very’ high risk rectal cancers with gross circumferential resection margin (CRM) involvement.

Duncan Samuel, Graeme Ian Murray, Leslie Samuel

Research output: Contribution to conference › Unpublished paper › peer-review

Fingerprint

Dive into the research topics of 'Neoadjuvant ‘Full Dose’ oxaliplatin/capecitabine/radiotherapy for MRI selected ‘very’ high risk rectal cancers with gross circumferential resection margin (CRM) involvement.'. Together they form a unique fingerprint.

Medicine & Life Sciences